Skip to main content
. 2020 Nov 27;22(1):66–73. doi: 10.1016/S1470-2045(20)30619-7

Figure 3.

Figure 3

The number of systemic anticancer treatment registrations observed per month, for immunotherapies (A), intravenous drugs (B), chemotherapies (C), and oral drugs (D)

The dashed horizontal line shows the mean number of registrations for the control period.